FDA OKs First Fecal Transplant Therapy for Recurrent C difficile FDA OKs First Fecal Transplant Therapy for Recurrent C difficile

Rebyota, a microbiota-based live biotherapeutic prepared from human stool, is intended for use after an individual has completed antibiotic treatment for recurrent C difficile infection.FDA Approvals
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Gastroenterology News Alert Source Type: news